NanoSurface Biomedical Acquires Silene Biotech to Expand Stem Cell-based Technologies

NanoSurface Biomedical announced today that it has acquired Silene Biotech, a Seattle biotechnology company focused on stem cell banking and services. This acquisition expands NanoSurface’s capabilities in developing human stem cell-based platforms and technologies to accelerate the development of new drugs.

NanoSurface NewsArianna KieserSeptember 25, 2019Press Release, Silene Biotech, NanoSurface Biomedical, Acquisition

National Assembly of South Korea Delegation Visits NanoSurface Biomedical

Members of the 4th Industrial Revolution committee from the National Assembly of the Republic of Korea visited NanoSurface Biomedical on May 17, 2019 to learn how the Greater Seattle Area is advancing in STEM and innovation. The National Assembly delegation visited leading Seattle-based companies including Amazon, Boeing, Microsoft, and NanoSurface Biomedical.

NanoSurface NewsArianna KieserMay 21, 2019

NanoSurface Launches Car(ina) Platform | New Drug Screening Platform with Structurally Matured Human Heart Tissues Derived from Stem Cells

NanoSurface Biomedical announced today the launch of the NanoSurface Car(ina)™ platform for highly predictive pre-clinical drug screening, using structurally matured human induced pluripotent stem cell (iPSC) derived heart tissues.

NanoSurface NewsArianna KieserMarch 26, 2019